In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Alice Biggane, Outcomes Innovation and Research Lead at Pfizer UK, to discuss how various PRO measures inform and impact reimbursement decisions for HTA driven markets. Together they unpack what data sources and methods exist for the quantification and understanding of HRQoL for cost-effectiveness decision making and the complex interplay between the need to reduce burden and increase transparency through standardization, while maintaining the crucial and nuanced balance of different stakeholder requirements. Tune in to learn how leading organizations are working to build more inclusive, efficient, and patient-focused clinical trials, and accelerating patient-access to new health technologies.
In this episode of TransPerfect LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences sits down with Andrew Lloyd, Director at Acaster-Lloyd...
DCTs have picked up significantly in previous years, catalyzed by the pandemic and a move to remote research. With this move comes a host...
In this episode, host Mark Wade is joined by Bill Byrom, the VP of Product Intelligence and Positioning at Signant Health, as they explore...
